| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 16.96 | 71.5% |
| Total Income | 16.96 | 71.5% |
| Expenditure | 61.82 | 32.4% |
| PBT | — | |
| Net Profit | -46.66 | 27.4% |
| OPM | — | |
| NPM | — | |
| EPS | -0.20 | 25.0% |
Gossamer Bio Reports Q1 2026 Financial Results; Cash Totals $99.2M
18 May 2026 · 18 May, 4:46 pm
Summary
Gossamer Bio announced its financial results for the first quarter ended March 31, 2026. The company reported cash, cash equivalents, and marketable securities totaling $99.2 million. Revenue from contracts with collaborators was $17.0 million, while R&D expenses amounted to $43.1 million. The net loss for the quarter was $46.7 million, or $0.20 per share. The company is planning to submit an NDA for seralutinib in PAH in September 2026, pending the outcome of a Pre-NDA meeting with the FDA.
Key Highlights
- 1
Gossamer Bio's cash, cash equivalents, and marketable securities totaled $99.2 million as of March 31, 2026.
- 2
Revenue from contracts with collaborators was $17.0 million for the quarter ended March 31, 2026, including $9.3 million of cost reimbursement revenue.
- 3
Research and Development expenses increased to $43.1 million for the quarter ended March 31, 2026, driven by costs associated with clinical trials for seralutinib.
- 4
General and Administrative expenses were $18.7 million for the quarter ended March 31, 2026, primarily due to one-time severance and related charges.
- 5
Net loss for the quarter ended March 31, 2026, was $46.7 million, or $0.20 basic net loss per share.
- 6
The company expects to submit an NDA for seralutinib in PAH in September 2026, subject to the outcomes of the Pre-NDA meeting.
- 7
An exchange offer has commenced to exchange any and all of its outstanding 5.00% Convertible Senior Notes due 2027.
Management Comments
Faheem Hasnain
"We are executing across multiple fronts at Gossamer. We have secured an in-person Pre-NDA Type B meeting with the FDA, reflecting our conviction in both the breadth of the PROSERA dataset and in the totality of evidence supporting seralutinib. Subject to the outcomes of that meeting, we expect to submit an NDA for seralutinib in PAH in September of this year. We see a regulatory path forward, toward an NDA submission, and we are executing against it." "The PROSERA CT FRI substudy results further strengthen our confidence in seralutinib. For the first time in a controlled PAH trial, we saw statistically significant imaging signals not only in the arterial compartment, but also across the venous vasculature and the parenchyma, and these signals correlated with clinical outcomes. This expands the seralutinib story well beyond arterial remodeling and provides structural evidence that seralutinib is acting across the lung in a manner consistent with its mechanism of action, even in a well-treated patient population.” “We have also taken steps to address our capital structure through a proposed exchange of our convertible notes, which we believe will strengthen our balance sheet as we approach this pivotal regulatory milestone. Our focus remains on disciplined execution as we look to advance seralutinib and prepare for the next phase of the Company’s growth.”
Informational and educational content only. Not investment advice.